aTyr Pharma Faces Legal Challenges Over Drug Efficacy Claims and Investor Misleading Allegations

### aTyr Pharma Faces Legal Scrutiny Over Drug Efficacy Claims

aTyr Pharma, Inc. is currently embroiled in significant legal challenges stemming from its recently disclosed issues surrounding the efficacy of its drug, Efzofitimod. The company faces allegations from multiple law firms, including the Gross Law Firm and Levi & Korsinsky, claiming that executives misled investors about the drug's ability to help patients taper off corticosteroids. These allegations intensified after aTyr announced on September 15, 2025, that its Phase 3 EFZO-FIT study did not meet its primary endpoint, which aimed at demonstrating a reduction in the mean daily oral corticosteroid dose at week 48. This revelation led to an overwhelming 83.2% drop in the company’s stock price within just two days, highlighting the potential impact of misleading statements on investor confidence and market performance.

The legal landscape for aTyr is further complicated by the initiation of class action lawsuits, encouraging affected shareholders to seek lead plaintiff status. The lawsuits encompass investors who purchased shares from November 7, 2024, to September 12, 2025, a period that coincides with the alleged misrepresentation of critical data regarding Efzofitimod. Legal firms are actively urging investors to register for participation before the December 8, 2025 deadline, emphasizing that joining the class action incurs no financial burden. This situation underscores the importance of transparency and accuracy in the biotech sector, particularly during clinical trials, where misleading information can have dire consequences for both investor trust and the company’s future.

In light of these challenges, aTyr Pharma is not only facing the repercussions of its financial disclosures but is also preparing for a crucial meeting with the U.S. Food and Drug Administration (FDA) in early 2026. This meeting aims to discuss the EFZO-FIT study results and explore potential regulatory pathways for Efzofitimod, which is being developed for the treatment of pulmonary sarcoidosis. While the company navigates these turbulent waters, it remains essential for aTyr to address the concerns raised by investors and the broader market regarding the integrity of its clinical trial data and its communication with stakeholders.

As aTyr Pharma grapples with these legal challenges, it also contemplates its financial future. The company recently reported a GAAP EPS loss of -$0.26, falling short of analyst expectations, and generated only $190,000 in revenue. These figures highlight the company's heavy reliance on its clinical pipeline and raise questions about its viability moving forward, especially in the face of mounting legal scrutiny. Affected investors are encouraged to stay informed and consider their options as the situation unfolds.